Akihisa Kaneko

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

E. Elgabry, M. Aoki, Yukari Nishito, 2017, Science Translational Medicine.

Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial

Shohei Kishishita, T. Kitazawa, M. Endo, 2022, Scientific Reports.

Prediction of clinical CYP3A4 induction using cryopreserved human hepatocytes

K. Takeda, M. Ishigai, A. Kaneko, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells

K. Takeda, Y. Aso, N. Sekiguchi, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the Emax Model

Motohiro Kato, S. Miyauchi, H. Shindoh, 2017, Drug Metabolism and Disposition.

A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor.

M. Tsuchiya, Y. Hirata, J. Nezu, 2005, Blood.

Title Simple evaluation method for CYP3A4 induction from human hepatocytes; The relative factor approach with an induction detection limit concentration based on the E max model

Shino Kuramoto, M. Ishigai, Motohiro Kato, 2022 .

Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial

Shohei Kishishita, T. Kitazawa, M. Endo, 2022, Scientific reports.

Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes.

Motohiro Kato, S. Iida, Shino Kuramoto, 2019, Drug metabolism and pharmacokinetics.